Innate Pharma Advances Immunotherapy with Robust Pipeline and Strategic Partnerships

Innate Pharma Strengthens Position in Immunotherapy Development

Innate Pharma SA, based in Marseille, France, announces its total shares outstanding and voting rights as of December 31, 2024, in compliance with French regulations. The company has a total of 83,830,336 ordinary shares, along with 6,494 Preferred Shares from 2016 and 7,581 from 2017. This results in a total of 84,585,576 theoretical voting rights, with 84,567,001 being exercisable. The distinction between theoretical and exercisable voting rights is crucial for stakeholders, as it highlights the shares with suspended voting rights versus those actively participating in governance. This transparency underscores Innate Pharma's commitment to regulatory compliance and shareholder engagement.

In the realm of immunotherapy, Innate Pharma's innovative approach leverages its proprietary ANKET® platform, aiming to develop multi-specific NK Cell Engagers. This technology positions the company as a frontrunner in creating novel cancer treatments. Its drug portfolio is diverse, featuring candidates such as IPH4502, a differentiated Antibody Drug Conjugate (ADC) targeting solid tumors, and lacutamab, an anti-KIR3DL2 monoclonal antibody specifically for cutaneous T-cell lymphomas. Additionally, the company is developing monalizumab, an anti-NKG2A monoclonal antibody, in collaboration with AstraZeneca for non-small cell lung cancer, demonstrating its commitment to addressing various oncology challenges.

Collaboration is a key driver of Innate Pharma's growth and innovation strategy. The company partners with major biopharmaceutical players like Sanofi and AstraZeneca, as well as prominent research institutions, enhancing its capacity to develop breakthrough therapies in cancer treatment. This collaborative ethos not only accelerates the research and development process but also fosters an environment of shared knowledge and resources, positioning Innate Pharma as a significant contributor to the evolving landscape of immuno-oncology. As a publicly traded entity on Euronext Paris and Nasdaq, the company affirms its international presence and commitment to advancing cancer therapeutics.

In addition to its robust pipeline, Innate Pharma's strategic partnerships with leading industry players reinforce its ability to bring innovative solutions to market. By leveraging expertise and resources from established biopharmaceutical companies, Innate Pharma enhances its research capabilities and accelerates the development of its promising drug candidates.

For more insights into Innate Pharma's pioneering work in cancer immunotherapy, visit their official website or follow their updates on social media platforms.